---
title: Smooth motor and behavioral fluctuations
nct_id: NCT07151378
phase: PHASE3
status: RECRUITING
sponsor: University Hospital Tuebingen
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07151378"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07151378"
last_fetched: "2026-05-10T14:07:54.216Z"
source: "Parkinson's Pathways (curated)"
---
# Smooth motor and behavioral fluctuations

**Goal (in five words):** Smooth motor and behavioral fluctuations

**Official Title:** Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

**Trial ID:** [NCT07151378](https://clinicaltrials.gov/study/NCT07151378)

## Key Facts

- **Phase:** PHASE3
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** University Hospital Tuebingen
- **Target Enrollment:** 150 participants
- **Start Date:** 2025-10-27
- **Completion Date:** 2030-09-22
- **Conditions:** PARKINSON DISEASE (Disorder)
- **Interventions:** LECIG (levodopa, carbidopa, entacapone intestinal gel), Best oral medication
- **Intervention Types:** DRUG

## Summary For Families

The goal is to reduce dopaminergic desensitization and the neuropsychiatric complications that can come with long-term intermittent levodopa, like affective fluctuations, impulse control problems, hypomanic or psychotic symptoms, and motor on/off swings. The approach uses LECIG, an intestinal gel combining levodopa, carbidopa and entacapone delivered through a PEG-J tube so levodopa is given continuously; carbidopa prevents peripheral breakdown, entacapone blocks COMT to extend levodopa's effect, and the steady infusion aims to smooth plasma levels and reduce both motor and behavioral swings compared with intermittent oral dosing. Eligible participants are adults 18 to 75 with L-Dopa responsive Parkinson's that began before age 65 and has lasted at least five years, currently taking oral levodopa with motor and affective dopaminergic fluctuations and hyperdopaminergic behaviors, with adequate cognition and retained insight if psychotic symptoms are present, and not already on device assisted therapies.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures. 2. Able to adhere to the study visit schedule and other protocol requirements. 3. Female Subject of childbearing potential1 and male subjects with female partner of childbearing potential1 is willing to use highly effective contraceptive methods during the study (adequate: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner2, sexual abstinence3).

  1. For the purpose of this document, a female is considered of childbearing potential (FCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. For the purpose of this document, a man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy
  2. Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the WOCBP trial participant and that the vasectomized partner has received medical assessment of the surgical success
  3. In the context of this guidance sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. 4. All subjects must agree not to share medication. 5. Diagnosis of Idiopathic PD, inclusive of familial PD and genetic forms of L-Dopa responsive PD Age 18 - 75 years 7. Age at Parkinson's disease onset before 65 years 8. Disease duration ≥ 5 years 9. Oral medication constant for four weeks prior to baseline visit 10. Oral treatment with L-Dopa and non-ergot dopamine agonist(s) (any preparation, any dosage) 11. Presence of dopaminergic motor fluctuations based on patient history 12. Presence of dopaminergic neuropsychiatric (affective) fluctuations based on patient history 13. Presence of behavioural hyperdopaminergic syndrome including clinically relevant neuropsychiatric behavioural abnormalities according Ardouin Behavioural Scale Section 1, hypomanic symptoms, psychosis + Section 4 hyperdopaminergic behaviours (score ≥ 3), eventually further accompanied by impulse control disorders, a/o dopamine dysregulation, syndrome, a/o hallucination - psychosis spectrum; in case symptoms of the hallucination/psychosis or hypomania-mania spectrum are present, retained insight is mandatory at the time of study enrolment

Exclusion Criteria:

* 1.Women during pregnancy and lactation. 2. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. 3. Participation in other clinical trials or observation period of competing trials over the past three months 4. Patients suffering from cognitive impairment (MoCA \< 21) will be excluded for the major reason to obtain valid Ardouin assessments that will be hampered in case cognitive impairment (and therefore insight) is too severe 5. Acute paranoid psychosis without retained insight (however impulse control disorder or dopamine dysregulation syndrome are not an exclusion criterion; illusions or (pseudo)-hallucinations are not an exclusion criterion as long as there is no endangerment of the patients themselves or other persons owing to clinical judgement; patients may be eligible after remission of psychosis/suicidality) 6. Severe depression according to ICD-10 criteria; however, affective fluctuations with intermittent depressive symptoms (reversed by dopaminergic medication) are not an exclusion criterion 7. Active suicidality without self-distancing (however, suicidal ideation/thoughts or passive wishes of being dead are not an exclusion criterion as long as the patient is credibly distancing from it). 8. General contraindications for intestinal L-Dopa therapy (according to Lecigon® Fachinformation) 9. Gastrointestinal contraindications against PEG-J tube placement 10. Tremor-dominant PD without dopaminergic response fluctuationt Pre-existing device assisted therapy (DAT) immediately before study enrolment including with DBS, LCIG/LECIG, or subcutaneous therapy with apomorphine or foslevodopa; if patient terminated pre-existing subcutaneous therapy, the patient will be eligible after having received oral dopamine replacement therapy for at least 3 months 12. Malignancy in a non-remitted stage
```

## Locations (3)

- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR, Dresden, Germany _(51.0509, 13.7383)_
  - Björn Falkenburger, Prof — (CONTACT) — +493514581154 — Bjoern.Falkenburger@ukdd.de
- Centre for Neurology, Department forNeurodegenerative Disease, and Hertie-Institute forClinical Brain Research, Tübingen, Germany _(48.5227, 9.0522)_
  - Daniel Weiss, Prof — (CONTACT) — 0049 (0) 7071-29-82340 — daniel.weiss@uni-tuebingen.de
- Parkinson-Klinik Ortenau GmbH & Co. KG, Wolfach, Germany _(48.2932, 8.2158)_
  - Wolgafng Jost, Prof — (CONTACT) — w.jost@parkinson-klinik.de

## Central Contacts

- Daniel Weiss, Prof — (CONTACT) — 0049 (0) 7071-29-82340 — Daniel.weiss@uni-tuebingen.de

---

*Canonical: https://parkinsonspathways.com/trial/NCT07151378*  
*HTML version: https://parkinsonspathways.com/trial/NCT07151378*  
*Source data: https://clinicaltrials.gov/study/NCT07151378*